Regenerys develops and sells regenerative medicine products in the streams requiring bioprocessing and biostorage. It offers Myskin, a product for the autologous treatment of serious burns and difficult to heal wounds using cultured allogeneic cells from the patient’s own skin; and Cryoskin, a medicine for the treatment of burns using autologous cells.
Regenerys also provides Adiposet, a service to facilitate better cosmetic outcomes in breast cancer surgery and other cosmetic procedures by enabling the storage and return of adipose tissue for lipomodellin. In addition, it offers third party bio-processing and bio-storage services through its laboratories.
Regenerys serves NHS and private healthcare providers in the United Kingdom and other parts of Europe. It began operation in 2011, with its headquarters in Cambridge in the United Kingdom.